Loading
NASDAQHealthcareBiotechnology
Latest quote
$21.2599
−$0.8701 · -3.93%
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Regular session
$21.2601
−$0.8699 · -3.93%
Regular session · ET · Market data may be delayed.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Day range
Current $21.2601
52-week range
Current $21.2601
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
32
Expensive
Sentiment
70
Bullish
Risk
36
Moderate Risk
Momentum
45
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Day range
Current $21.2601
52-week range
Current $21.2601
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 22.5M USD | 45.56M USD | 14.09M USD | 102.69M USD | — |
| Cost of goods sold | 59K USD | — | — | — | — |
| Gross profit | 22.44M USD | 45.56M USD | 14.09M USD | 102.69M USD | — |
| Research and development | 141.83M USD | 151.41M USD | 159.42M USD | 86.74M USD | 28.97M USD |
| Selling, general, and administrative | 106.3M USD | 70.45M USD | 37.63M USD | 19.51M USD | 5.68M USD |
| Operating expenses | 248.13M USD | 221.85M USD | 197.06M USD | 106.25M USD | 34.98M USD |
| Interest income | 27.59M USD | 16.88M USD | 10.22M USD | — | — |
| Interest expense | — | — | 6.8M USD | 287K USD | 411K USD |
| Depreciation and amortization | 220K USD | 113K USD | 49K USD | 9K USD | 5K USD |
| Operating income | −225.68M USD | −176.29M USD | −182.97M USD | −3.56M USD | −34.98M USD |
| Net income | −203.82M USD | −241.6M USD | −176.94M USD | −22.63M USD | −41.79M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$51.33
141.44% upsidePrice history unavailable
High $58.00Average $51.33Low $45.00Funds reporting this stock among their holdings, ordered by reported position size.
Capital Group U.S. Small and Mid Cap ETFCGMM16.81M0.47%3.55B USD0.51%$31.395-0.27%
iShares Biotechnology ETFIBB12.94M0.12%10.4B USD0.44%$200.28-1.50%
Vanguard Health Care ETFVHT4.98M0.02%22B USD0.09%$313.21-0.67%
ALPS Medical Breakthroughs ETFSBIO3.36M1.78%188.26M USD0.50%$53.87-0.48%
Fidelity Fundamental Small-Mid Cap ETFFFSM1.31M0.08%1.44B USD0.43%$33.915-0.25%
iShares ESG Aware MSCI USA Small-Cap ETFESML1.13M0.04%2.77B USD0.17%$52.29-0.06%
Fidelity Nasdaq Composite Index ETFONEQ765.79K0.01%10.94B USD0.21%$107.01-1.33%
Fidelity MSCI Health Care Index ETFFHLC719.07K0.02%3.54B USD0.08%$80.875-0.69%Capital Group U.S. Small and Mid Cap ETFCGMMiShares Biotechnology ETFIBBVanguard Health Care ETFVHTALPS Medical Breakthroughs ETFSBIOFidelity Fundamental Small-Mid Cap ETFFFSMiShares ESG Aware MSCI USA Small-Cap ETFESMLFidelity Nasdaq Composite Index ETFONEQFidelity MSCI Health Care Index ETFFHLCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
